Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era
Journal of the National Comprehensive Cancer Network · 2025-04 · 23 (4)
DOI: 10.6004/jnccn.2024.7086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025-04. Verfasst von Dongxiang Wen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background
Chemotherapy combined with immunotherapy (CT-IO) has become the first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). Locoregional radiotherapy (LRRT) following chemotherapy has been shown to significantly improve survival outcomes in patients with dmNPC. However, it remains unclear whether LRRT provides additional benefits in the context of CT-IO. Furthermore, there is no consensus on how to identify the optimal patient population for LRRT after first-line CT-IO.
Methods
This study included patients with dmNPC who received platinum-based palliative chemotherapy and anti–PD-1 immunotherapy, with or without LRRT. Progression-free survival (PFS) was assessed in LRRT and non-LRRT groups using inverse probability of treatment weighting (IPTW) to mitigate selection bias. Median PFS (mPFS) at the 6-month landmark was estimated using Kaplan-Meier analyses. A novel prognostic nomogram was developed and validated to predict PFS and stratify patients by risk. Using prognostic scores from the nomogram, a model-based tree approach was employed to assess stratified treatment outcomes and identify the ideal candidates for LRRT.
Results
A total of 500 patients were included, with 367 receiving LRRT and 133 not receiving it. At the 6-month conditional landmark, IPTW-adjusted Kaplan-Meier curves demonstrated significantly improved survival in the LRRT group compared with the non-LRRT group (mPFS, not reached vs 21.5 months; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China.
- Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China.
- Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China.
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China.
Zitieren
APA
Wen, D., Jin, J., Lin, J., Luo, M., Liu, R., Liu, S., Xiong, L., Liu, L., Tang, L., Mai, H., Guo, S., Liang, Y., & Chen, Q. (2025). Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era. Journal of the National Comprehensive Cancer Network, 23(4). https://doi.org/10.6004/jnccn.2024.7086
Vancouver
Wen D, Jin J, Lin J, Luo M, Liu R, Liu S, et al. Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era. Journal of the National Comprehensive Cancer Network. 2025;23(4). doi:10.6004/jnccn.2024.7086
BibTeX
@article{Wen2025,
author = {Wen, Dongxiang and Jin, Jing and Lin, Jieyi and Luo, Meijuan and Liu, Rongping and Liu, Siqi and Xiong, Longbin and Liu, Liting and Tang, Linquan and Mai, Haiqiang and Guo, Shanshan and Liang, Yujing and Chen, Qiuyan},
title = {Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
volume = {23},
number = {4},
doi = {10.6004/jnccn.2024.7086}
}
EUVIMED